阅读说明：本技术 治疗鼻咽癌的喹啉衍生物 (Quinoline derivatives for treating nasopharyngeal carcinoma ) 是由 王善春 沈军 韩溪 王训强 汤少男 曹淑情 张喜全 于浩 潘茂琼 于 2019-03-07 设计创作，主要内容包括：本发明提供了一种治疗鼻咽癌的衍生物,及其在制备用于肿瘤治疗的药物组合物的用途,具体而言,本发明设计喹啉衍生物1-[[[4-(4-氟-2-甲基-1H-吲哚-5-基)氧基-6-甲氧基喹啉-7-基]氧基]甲基]环丙胺在治疗鼻咽癌中的用途,(I)。<Image he="255" wi="342" file="DEST_PATH_IMAGE002.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(The invention provides a derivative for treating nasopharyngeal carcinoma and application thereof in preparing a pharmaceutical composition for treating tumors, in particular to a quinoline derivative 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl [ ]]Oxy radical]Methyl radical]Use of cyclopropylamine in the treatment of nasopharyngeal carcinoma, (I).)

A method for the prevention and/or treatment of nasopharyngeal carcinoma, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof

The method of claim 1, wherein the nasopharyngeal carcinoma is keratinized squamous cell carcinoma or non-keratinized nasopharyngeal carcinoma.

The method of claim 2, wherein the non-keratinizing nasopharyngeal carcinoma is differentiated or non-differentiated.

The method of claim 1, wherein the nasopharyngeal carcinoma is carcinoma in situ or invasive.

The method of claim 4, wherein the invasive cancer is squamous cell carcinoma, adenocarcinoma, microaneurysmic carcinoma, alveolar cell carcinoma, or undifferentiated nasopharyngeal carcinoma.

The method of claim 1, wherein the nasopharyngeal carcinoma is advanced and/or metastatic nasopharyngeal carcinoma.

The method of claim 6, wherein said advanced and/or metastatic nasopharyngeal carcinoma metastasizes to cervical lymph, spleen and/or lung.

The method of claim 1, wherein the nasopharyngeal carcinoma is not surgically resectable.

The method of claim 1, wherein said nasopharyngeal carcinoma has previously received chemotherapy, monoclonal antibody therapy and/or radiation therapy.

The method of claim 9, wherein said nasopharyngeal carcinoma patient has previously undergone a progression of disease after chemotherapy, monoclonal antibody treatment and/or radiation treatment.

The method of claim 10, wherein the patient with nasopharyngeal carcinoma has previously received a chemotherapeutic agent comprising gemcitabine, capecitabine, cisplatin, lobaplatin, nedaplatin, 5-fluorouracil, paclitaxel, docetaxel, and/or cyclophosphamide; previous treatments for monoclonal antibodies received by patients with nasopharyngeal carcinoma include cetuximab, bevacizumab, and/or SHR-1210.

The process according to any one of claims 1 to 11, wherein the pharmaceutically acceptable salt of the compound of formula (I) is a salt of compound I with any of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1, 2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid; preferably the hydrochloride salt, more preferably the dihydrochloride salt; preferably, the dose administered is from 2mg to 20 mg, more preferably from mg to 20 mg; preferably, the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered with an interval between the administration period and the withdrawal period, more preferably with a ratio of the administration period to the withdrawal period in days of 2: 0.5-5.

The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament or pharmaceutical composition for the treatment of nasopharyngeal carcinoma,

a pharmaceutical composition for treating nasopharyngeal carcinoma, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier

A kit comprising (a) at least one unit dose of a pharmaceutical composition of a compound of formula (I) or a pharmaceutically acceptable salt thereof and (b) instructions for treating nasopharyngeal carcinoma